Prospective study for establishing minimal clinically important differences in patients with surgery for lower extremity metastases

Authors

  • M. E. R. Bongers Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Orthopaedic Surgery, Academic University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • O. Q. Groot Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Orthopaedic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
  • Q. C. B. S. Thio Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  • J. J. Verlaan Department of Orthopaedic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
  • E. T. Newman Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  • S. A. Lozano-Calderon Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  • J. H. Schwab Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

DOI:

https://doi.org/10.1080/0284186X.2021.1890333

Keywords:

Minimal clinically important difference, anchor-based, PROMIS, ; lower extremity metastases, pathologic fracture, prophylactic fixation

Abstract

Background

The clinical relevance of patient-reported outcomes score changes is often unclear. Especially in patients undergoing surgery due to lower extremity metastases – where surgery is performed in the palliative setting and the goal is to optimize functional mobility, relieve pain and improve overall quality of life. This study assessed the minimal clinically important difference (MCID) of Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference, Cancer-specific Physical Function, and Global (Physical and Mental Health) in patients treated surgically for impending or completed pathologic fractures.

Methods

Patients undergoing surgery for osseous metastasis of the lower extremity because of an impending or completed pathologic fracture were consecutively enrolled in this tertiary center study. Patients completed the three PROMIS questionnaires preoperatively (n = 56) and at postoperative follow-up (n = 33) assessment one to three months later. Of the 23 patients that did not complete the postoperative survey, 5 patients died within 1–3 months and 18 patients were alive at 3-months but did not respond or show up at their postoperative consult. Thirty-one patients (94%) of the 33 included patients reported at least minimal improvement and two patients (6.1%) no change 1–3 months after the surgery based on an anchor-based approach.

Results

The PROMIS MCIDs (95% confidence interval) for Pain Interference was 7.5 (3.4–12), Physical Function 4.1 (0.6–7.6), Global Physical Health 4.2 (2.0–6.6), and Global Mental Health 0.8 (−4.5–2.9).

Conclusion

This prospective study successfully defined a MCID for PROMIS Pain Interference of 7.5 (3.4–12), PROMIS Physical Function of 4.1 (0.6–7.6), and Global Physical Health of 4.2 (2.0–6.6) in patients with (impending) pathological fractures due to osseous metastases in the lower extremity; no MCID could be established for PROMIS Global Mental Health. Defining a narrower MCID value for each subpopulation requires a large, prospective, multicenter study. Nevertheless, the provided MCID values allow guidance to clinicians to evaluate the impact of surgical treatment on a patient’s QoL.

Level of evidence

Level II Diagnostic study

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2021-06-03

How to Cite

Bongers, M. E. R., Groot, O. Q., Thio, Q. C. B. S., Verlaan, J. J., Newman, E. T., Lozano-Calderon, S. A., & Schwab, J. H. (2021). Prospective study for establishing minimal clinically important differences in patients with surgery for lower extremity metastases. Acta Oncologica, 60(6), 714–720. https://doi.org/10.1080/0284186X.2021.1890333

Issue

Vol. 60 No. 6 (2021): Acta Oncologica

Section

Articles